Malignant melanoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:04:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malignant melanoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of ipilimumab and nivolumab to observe immune system changes in patients with unresectable stage III or IV melanoma https://clinicaltrials.eu/trial/a-study-of-ipilimumab-and-nivolumab-to-observe-immune-system-changes-in-patients-with-unresectable-stage-iii-or-iv-melanoma/ Wed, 29 Apr 2026 15:09:33 +0000 https://clinicaltrials.eu/trial/a-study-of-ipilimumab-and-nivolumab-to-observe-immune-system-changes-in-patients-with-unresectable-stage-iii-or-iv-melanoma/ This study focuses on patients with unresectable stage III–IV melanoma, which is a serious type of skin cancer that cannot be removed by surgery. The purpose of the study is to compare two different ways of giving medication to see how they affect the immune system’s response to the cancer. One approach involves using ipilimumab, an immunotherapy drug that helps the body’s own defenses fight cancer, alongside nivolumab. In one part of the study, ipilimumab is given through an intradermal injection, which means the medicine is injected just under the surface of the skin, while nivolumab is given through an intravenous infusion, which is a liquid delivered directly into a vein.

The other part of the study uses the standard method where both ipilimumab and nivolumab are given through intravenous infusion. Researchers will look at how these different methods change the tumour microenvironment, which refers to the area immediately surrounding the cancer cells. The study will also monitor the activity of T cells, which are specific white blood cells that play a key role in the body’s ability to attack harmful cells, as well as Tregs, a type of cell that can sometimes prevent the immune system from working too strongly against the cancer.

]]> Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies https://clinicaltrials.eu/trial/study-of-bnt111-and-cemiplimab-in-patients-with-advanced-melanoma-who-have-not-responded-to-other-therapies/ Wed, 29 Apr 2026 15:07:57 +0000 https://clinicaltrials.eu/trial/study-of-bnt111-and-cemiplimab-in-patients-with-advanced-melanoma-who-have-not-responded-to-other-therapies/ The study involves patients with advanced melanoma, a type of skin cancer that has reached stage III or IV. Melanoma at these stages is difficult to remove surgically and often does not respond to standard treatment. Two drugs are being tested in the study: BNT111 and cemiplimab. BNT111 is a new drug that contains substances such as gindameran, vibosameran, enomimeran, and ontasameran, while cemiplimab is a drug already used to treat certain cancers.

The aim of the study is to see how well these drugs work together or separately in fighting melanoma that does not respond to other therapies. Study participants will be randomly assigned to one of two groups, where they will receive either both drugs or only one of them. The study aims to assess whether the combination of these drugs can increase the effectiveness of treatment compared to using them separately.

The study involves regular visits during which patients will receive the drugs as intravenous infusions. The study will last up to 104 weeks and is scheduled to end in late 2025. During the study, the body’s response to treatment and any side effects will be monitored. The goal is to assess whether the drugs can reduce the size of the tumor or slow its growth.

]]> Study of local treatment options for large metastases in patients with BRAF V600 mutated melanoma receiving Encorafenib and Binimetinib combination therapy https://clinicaltrials.eu/trial/study-on-surgery-or-radiotherapy-for-large-metastases-in-patients-with-braf-v600-mutated-melanoma-treated-with-encorafenib-and-binimetinib/ Wed, 29 Apr 2026 15:03:55 +0000 https://clinicaltrials.eu/trial/study-on-surgery-or-radiotherapy-for-large-metastases-in-patients-with-braf-v600-mutated-melanoma-treated-with-encorafenib-and-binimetinib/ This study focuses on patients with melanoma that has a specific genetic change called BRAF V600 mutation. The melanoma must be either inoperable (cannot be removed by surgery) or has spread to other parts of the body. The study will test a combination of two medications: encorafenib and binimetinib, which are drugs that target specific proteins involved in cancer growth.

The purpose of this study is to determine how well patients respond to local treatments (such as radiotherapy, surgery, or electrochemotherapy) when they are already receiving encorafenib and binimetinib. These local treatments will be used on specific tumor sites while patients continue taking their regular medication.

During the study, patients will receive encorafenib and binimetinib as oral medications daily. When certain tumors remain stable or continue to grow while other tumors are responding to treatment, doctors may use local treatments like radiotherapy, surgery, or electrochemotherapy to target these specific areas. Patients will be monitored regularly to check how their cancer responds to this combination of treatments and to watch for any side effects.

]]> Study of Regorafenib with BRAF/MEK-Inhibitor Combination for Patients with Advanced Melanoma After Previous Treatment https://clinicaltrials.eu/trial/study-of-regorafenib-with-braf-mek-inhibitor-combination-for-patients-with-advanced-melanoma-after-previous-treatment/ Wed, 29 Apr 2026 14:59:14 +0000 https://clinicaltrials.eu/trial/study-of-regorafenib-with-braf-mek-inhibitor-combination-for-patients-with-advanced-melanoma-after-previous-treatment/ This clinical trial is focused on studying the effects of a medication called regorafenib on patients with advanced melanoma, a type of skin cancer. The study is specifically for patients who have already received treatment for their melanoma but need additional options. Regorafenib, also known by its code name BAY73-4506, is provided in the form of film-coated tablets and is taken orally, meaning it is swallowed. The purpose of the study is to evaluate how well regorafenib works when added to a combination of other treatments known as BRAF and MEK inhibitors, which are used to target specific mutations in melanoma cells.

Participants in the study will receive regorafenib in addition to their existing treatment regimen. The study will observe how the cancer responds to this combination, looking for any reduction in tumor size or slowing of disease progression. The trial will also monitor the overall health and safety of participants, checking for any side effects or changes in their condition. The study aims to provide more information on the potential benefits of regorafenib for patients with melanoma who have specific genetic mutations, such as the BRAF V600 mutation.

The trial will last for a period of time, during which participants will be regularly assessed to track their response to the treatment. This includes medical examinations and tests to ensure the safety and effectiveness of the medication. The study hopes to offer new insights into treatment options for advanced melanoma, potentially improving outcomes for patients with this challenging condition.

]]> Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery https://clinicaltrials.eu/trial/study-of-nivolumab-and-relatlimab-for-patients-with-stage-iii-iv-melanoma-after-surgery/ Wed, 29 Apr 2026 14:57:11 +0000 https://clinicaltrials.eu/trial/study-of-nivolumab-and-relatlimab-for-patients-with-stage-iii-iv-melanoma-after-surgery/ This clinical trial is focused on studying the treatment of Stage III-IV Melanoma, a type of skin cancer that has been completely removed through surgery. The study is comparing two treatments: a combination of two medications, Nivolumab and Relatlimab, and a single medication, Nivolumab alone. These medications are given as a solution for infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to see how effective the combination treatment is compared to the single medication in preventing the return of melanoma after surgery. Participants in the study will receive either the combination of Nivolumab and Relatlimab or Nivolumab alone. Some participants may receive a placebo, which looks like the treatment but does not contain the active medication. The study will last for up to 12 months, during which participants will be monitored regularly to check for any signs of the cancer returning and to assess their overall health.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether the combination of Nivolumab and Relatlimab offers better protection against the return of melanoma compared to Nivolumab alone. This research could help improve future treatment options for people with this type of skin cancer.

]]> Study of INCB099280 and Ipilimumab for Patients with Advanced Solid Tumors https://clinicaltrials.eu/trial/study-of-incb099280-and-ipilimumab-for-patients-with-advanced-solid-tumors/ Wed, 29 Apr 2026 14:56:53 +0000 https://clinicaltrials.eu/trial/study-of-incb099280-and-ipilimumab-for-patients-with-advanced-solid-tumors/ This clinical trial is focused on studying the effects of a new treatment combination for people with certain types of solid tumors, which are abnormal masses of tissue that can occur in various parts of the body. The study involves two treatments: a medication with the code name INCB099280, which is taken as a film-coated tablet, and Ipilimumab, known by the brand name YERVOY, which is given as an infusion directly into the bloodstream. The purpose of the study is to determine how safe and tolerable this combination is for patients with advanced solid tumors.

Participants in the study will receive the treatment combination over a period of time, with INCB099280 being taken orally and Ipilimumab administered through an intravenous infusion. The study will monitor the participants for any side effects or reactions to the treatment. The goal is to find the right dose that is both safe and effective for patients. The study will also compare the effects of the treatment combination to a placebo to better understand its impact.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their treatment. These tests will help researchers understand how the treatment affects the body and whether it helps control the growth of the tumors. The study is expected to continue for several years, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness.

]]> Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ Wed, 29 Apr 2026 14:29:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ This clinical trial is focused on studying a type of skin cancer called metastatic or recurrent melanoma. The study is testing a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy involves using the patient’s own immune cells, specifically T cells, which are modified to better recognize and attack cancer cells. The study also involves a medication called nivolumab, which is known by the brand name OPDIVO. Nivolumab is a type of drug that helps the immune system fight cancer by blocking a protein that stops the immune system from attacking cancer cells.

The purpose of this study is to evaluate the safety and how well the treatment works when using ATL001 alone and in combination with nivolumab. Participants in the study will receive these treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor participants over a period of time to observe any side effects and to see how the cancer responds to the treatment. The study aims to understand if this combination can help control the cancer and improve outcomes for patients with metastatic or recurrent melanoma.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study will also look at changes in the size of the tumor and overall survival rates. This research is important for developing new ways to treat melanoma and potentially improve the quality of life for those affected by this disease.

]]> Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ro7198457-and-pembrolizumab-for-patients-with-untreated-advanced-melanoma/ Wed, 29 Apr 2026 14:29:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ro7198457-and-pembrolizumab-for-patients-with-untreated-advanced-melanoma/ This clinical trial is focused on studying the treatment of Advanced Melanoma, a type of skin cancer that has spread to other parts of the body. The study is evaluating the effectiveness and safety of a new treatment combination. The treatment involves two medications: RO7198457, also known as Autogene Cevumeran, and Pembrolizumab, which is marketed under the name Keytruda. RO7198457 is a gene therapy product that uses mRNA technology, while Pembrolizumab is a type of protein-based medication that helps the immune system fight cancer.

The purpose of this study is to compare the combination of RO7198457 and Pembrolizumab against Pembrolizumab alone in patients who have not received prior treatment for their advanced melanoma. The study will monitor how long patients live without their cancer getting worse, known as progression-free survival. Participants will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time the safety and effectiveness of the treatments will be closely observed.

Throughout the study, researchers will also look at other important factors, such as the overall survival of patients, the response of the cancer to the treatment, and any changes in the patients’ quality of life. Additionally, the study will track any side effects experienced by participants to ensure the treatments are safe. This trial aims to provide valuable information on whether the combination of RO7198457 and Pembrolizumab offers a better treatment option for patients with advanced melanoma compared to Pembrolizumab alone.

]]> Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/ Wed, 29 Apr 2026 14:28:56 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-advanced-melanoma-with-braf-v600e-k-mutation/ This clinical trial is focused on studying a type of skin cancer called melanoma, specifically when it has spread to other parts of the body or cannot be removed by surgery. The study is looking at patients with a specific genetic change known as the BRAF V600E/K mutation. The trial will test the effectiveness of a combination of medications: Encorafenib, Binimetinib, and Pembrolizumab. Encorafenib is taken as a capsule, Binimetinib as a tablet, and Pembrolizumab is given through an infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to compare the effects of the combination of Encorafenib, Binimetinib, and Pembrolizumab against a placebo combined with Pembrolizumab. Participants will be randomly assigned to receive either the combination of the three medications or the placebo with Pembrolizumab. The study will last for up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of the melanoma.

This trial aims to determine if the combination of these medications can improve outcomes for patients with this specific type of melanoma. The study will also assess the safety of the medication combination and monitor any side effects that may occur. Participants will be closely observed by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s effectiveness.

]]> Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-braf-v600e-k-mutation-positive-melanoma-after-anti-pd-1-therapy/ Wed, 29 Apr 2026 14:28:40 +0000 https://clinicaltrials.eu/trial/study-of-encorafenib-binimetinib-and-pembrolizumab-for-patients-with-braf-v600e-k-mutation-positive-melanoma-after-anti-pd-1-therapy/ This clinical trial is focused on studying a type of skin cancer called melanoma, specifically in patients who have a mutation known as BRAF V600E/K. This mutation can make the cancer more aggressive and harder to treat. The study is looking at patients whose melanoma has either spread to other parts of the body or cannot be removed by surgery. These patients have already been treated with a type of therapy called anti-PD-1 therapy, which helps the immune system fight cancer, but their cancer has continued to grow.

The purpose of the study is to compare two different treatment combinations to see which is more effective. One group of participants will receive a combination of three medications: encorafenib, binimetinib, and pembrolizumab. The other group will receive a combination of two medications: nivolumab and ipilimumab. These medications are given to help the immune system target and destroy cancer cells. Encorafenib and binimetinib are taken as tablets, while pembrolizumab, nivolumab, and ipilimumab are given through an infusion into a vein.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of time, during which participants will receive their assigned treatment and be monitored regularly by the study team. The goal is to see which treatment combination works better in controlling the cancer and improving the participants’ health. The study will also look at the safety of the treatments and any side effects that may occur. Participants will have regular check-ups and tests to track their progress and the effects of the treatment.

]]> Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-solid-tumors-who-have-not-received-immunotherapy/ Wed, 29 Apr 2026 14:27:04 +0000 https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-solid-tumors-who-have-not-received-immunotherapy/ This clinical trial is focused on studying the effects of a new treatment called INCB099280 on certain types of cancer known as solid tumors. These tumors are advanced or have come back after treatment, and the patients have not previously received a type of treatment called immunotherapy. The purpose of the study is to understand how safe and tolerable the treatment is, and to see how well it works in managing these tumors.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.

]]>